This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Tuberculosis/ Other Mycobacterium  • Immunization  • World Health  • Pulmonary Diseases  • Pulmonary Diseases, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

M. J. Friedrich

JAMA. 2005;293:2703-2705.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In 1993, the World Health Organization declared tuberculosis (TB) a global emergency and called on the biomedical community to redouble its efforts to combat this scourge. Designing a better TB vaccine was one of the goals. The hard work of many researchers is now beginning to yield results, with a number of new vaccine candidates in phase 1 clinical trials and more on the way.

About 2 billion people—roughly one third of the world’s population—are estimated to be infected with TB. It remains latent in all but 5% to 10% of those infected—as long as the immune system is healthy. However, in individuals whose immune systems are compromised by HIV, poor nutrition, or other factors, the outlook is much more dire. The disease kills about 2 million individuals annually.

An attenuated strain of Mycobacterium bovis, shown here (blue) being engulfed by a macrophage, is used to . . . [Full Text of this Article]

BUILDING A BETTER BCG



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?